Abstract
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
Highlights
Enterovirus A71 (EV-A71) is one of the most important neurotropic viruses and poses a serious threat to public health worldwide
We summarize the tive countermeasure against EV-A71 infection and epidemic
The study results showed that the Sinovac vaccine demonstrated the long-term persistence of immunogenicity within five years [24]
Summary
Enterovirus A71 (EV-A71) is one of the most important neurotropic viruses and poses a serious threat to public health worldwide. Genotype B is divided into subgenotypes B1 to B5. Genotype C is divided into subgenotypes C1 to C5, and C4 is further divided into C4 a and C4 b. Subgenotypes B3, B4, C1, and C2 co-circulated in the Asia–Pacific region from 1999 to 2016. C4 is the most prevalent genotype circulating in China; C1 and C2 are most prevalent in Europe while B4 and B5 are most prevalent in other regions [6,7,8]. The viral genome within its icosahedral capsid is flanked by highly structured 50 and 30 untranslated regions (UTR) and is polyadenylated at its 30 end.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have